A Novel Oncogenic BTK Isoform is Overexpressed in Colon Cancers and Required for RAS-mediated Transformation

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2016 Jan 26

PMID 26804170

Citations 43

Authors

E Grassilli

F Pisano

A Cialdella

S Bonomo

C Missaglia

M G Cerrito

L Masiero

L Ianzano

F Giordano

V Cicirelli

R Narloch

F DAmato

B Noli

G L Ferri

B E Leone

G Stanta

S Bonin

K Helin

R Giovannoni

M Lavitrano

Affiliations

Soon will be listed here.

Abstract

Bruton's tyrosine kinase (BTK) is essential for B-cell proliferation/differentiation and it is generally believed that its expression and function are limited to bone marrow-derived cells. Here, we report the identification and characterization of p65BTK, a novel isoform abundantly expressed in colon carcinoma cell lines and tumour tissue samples. p65BTK protein is expressed, through heterogeneous nuclear ribonucleoprotein K (hnRNPK)-dependent and internal ribosome entry site-driven translation, from a transcript containing an alternative first exon in the 5'-untranslated region, and is post-transcriptionally regulated, via hnRNPK, by the mitogen-activated protein kinase (MAPK) pathway. p65BTK is endowed with strong transforming activity that depends on active signal-regulated protein kinases-1/2 (ERK1/2) and its inhibition abolishes RAS transforming activity. Accordingly, p65BTK overexpression in colon cancer tissues correlates with ERK1/2 activation. Moreover, p65BTK inhibition affects growth and survival of colon cancer cells. Our data reveal that BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach.

Citing Articles

Regulation of HNRNP family by post-translational modifications in cancer.

Li B, Wen M, Gao F, Wang Y, Wei G, Duan Y Cell Death Discov. 2024; 10(1):427.

PMID: 39366930 PMC: 11452504. DOI: 10.1038/s41420-024-02198-7.

Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting.

Jiao L, Tao Y, Ding H, Wu F, Liu Y, Li C 3 Biotech. 2024; 14(9):215.

PMID: 39220827 PMC: 11358563. DOI: 10.1007/s13205-024-04053-z.

Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states.

Lin D, Kueffer L, Juneja P, Wales T, Engen J, Andreotti A Elife. 2024; 12.

PMID: 38189455 PMC: 10945472. DOI: 10.7554/eLife.89489.

Differential gene expression of immunity and inflammation genes in colorectal cancer using targeted RNA sequencing.

Holubekova V, Loderer D, Grendar M, Mikolajcik P, Kolkova Z, Turyova E Front Oncol. 2023; 13:1206482.

PMID: 37869102 PMC: 10586664. DOI: 10.3389/fonc.2023.1206482.

Influence of Bruton's Tyrosine Kinase (BTK) on Epithelial-Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC).

Leichtle F, Betzler A, Eizenberger C, Lesakova K, Ezic J, Drees R Int J Mol Sci. 2023; 24(17).

PMID: 37685940 PMC: 10487612. DOI: 10.3390/ijms241713133.

References

Spatuzza C, Schiavone M, Di Salle E, Janda E, Sardiello M, Fiume G . Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk. Nucleic Acids Res. 2008; 36(13):4402-16. PMC: 2490745. DOI: 10.1093/nar/gkn413. View

Li T, Tsukada S, Satterthwaite A, Havlik M, Park H, Takatsu K . Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity. 1995; 2(5):451-60. DOI: 10.1016/1074-7613(95)90026-8. View

Kang S, Wahl M, Chu J, Kitaura J, Kawakami Y, Kato R . PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 2001; 20(20):5692-702. PMC: 125669. DOI: 10.1093/emboj/20.20.5692. View

Gao B, Roux P . Translational control by oncogenic signaling pathways. Biochim Biophys Acta. 2014; 1849(7):753-65. DOI: 10.1016/j.bbagrm.2014.11.006. View

Komar A, Mazumder B, Merrick W . A new framework for understanding IRES-mediated translation. Gene. 2012; 502(2):75-86. PMC: 3361623. DOI: 10.1016/j.gene.2012.04.039. View

Guha M . Imbruvica--next big drug in B-cell cancer--approved by FDA. Nat Biotechnol. 2014; 32(2):113-5. DOI: 10.1038/nbt0214-113. View

De Luca A, Maiello M, DAlessio A, Pergameno M, Normanno N . The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16 Suppl 2:S17-27. DOI: 10.1517/14728222.2011.639361. View

Novero A, Ravella P, Chen Y, Dous G, Liu D . Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014; 3(1):4. PMC: 3913970. DOI: 10.1186/2162-3619-3-4. View

Rawlings D, Saffran D, Tsukada S, Largaespada D, Grimaldi J, Cohen L . Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science. 1993; 261(5119):358-61. DOI: 10.1126/science.8332901. View

10.

Eifert C, Wang X, Kokabee L, Kourtidis A, Jain R, Gerdes M . A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer. 2013; 52(10):961-75. PMC: 5006942. DOI: 10.1002/gcc.22091. View

11.

Salamov A, Nishikawa T, Swindells M . Assessing protein coding region integrity in cDNA sequencing projects. Bioinformatics. 1998; 14(5):384-90. DOI: 10.1093/bioinformatics/14.5.384. View

12.

Park H, Wahl M, Afar D, Turck C, Rawlings D, Tam C . Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity. 1996; 4(5):515-25. DOI: 10.1016/s1074-7613(00)80417-3. View

13.

Pow D, Crook D . Extremely high titre polyclonal antisera against small neurotransmitter molecules: rapid production, characterisation and use in light- and electron-microscopic immunocytochemistry. J Neurosci Methods. 1993; 48(1-2):51-63. DOI: 10.1016/s0165-0270(05)80007-x. View

14.

Burger J . Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2013; 9(1):44-9. DOI: 10.1007/s11899-013-0188-8. View

15.

Notari M, Neviani P, Santhanam R, Blaser B, Chang J, Galietta A . A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 2005; 107(6):2507-16. PMC: 1895740. DOI: 10.1182/blood-2005-09-3732. View

16.

Fang J, Richardson B . The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005; 6(5):322-7. DOI: 10.1016/S1470-2045(05)70168-6. View

17.

Bomsztyk K, Denisenko O, Ostrowski J . hnRNP K: one protein multiple processes. Bioessays. 2004; 26(6):629-38. DOI: 10.1002/bies.20048. View

18.

Yao L, Kawakami Y, Kawakami T . The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C. Proc Natl Acad Sci U S A. 1994; 91(19):9175-9. PMC: 44770. DOI: 10.1073/pnas.91.19.9175. View

19.

Wurth L, Gebauer F . RNA-binding proteins, multifaceted translational regulators in cancer. Biochim Biophys Acta. 2014; 1849(7):881-6. DOI: 10.1016/j.bbagrm.2014.10.001. View

20.

Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame A, Shokat K . ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol. 2001; 3(3):325-30. DOI: 10.1038/35060131. View